DSIP

Mechanism

DSIP is a small peptide that promotes deep sleep and helps regulate stress hormones. It works by influencing brain chemicals involved in sleep cycles and may help reduce anxiety by improving sleep quality and lowering stress hormone levels.

Effects

## Central Nervous System — Sleep Architecture [Tier 2 — Moderate Human Data] DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, nonapeptide) was first isolated from rabbit cerebral venous blood during electrically induced sleep (Schoenenberger & Monnier, 1977). Its name is somewhat misleading — DSIP does not simply "induce" sleep like a sedative. Rather, it modulates sleep ARCHITECTURE, specifically promoting slow-wave sleep (SWS, stages N3) characterized by high-amplitude delta waves (0.5-4 Hz) on EEG. **EEG Studies — What the Data Actually Show:** - In human sleep studies, IV DSIP administration (25-30 nmol/kg) increased delta wave power density (measured by spectral analysis) by 15-35% during the first and second sleep cycles compared to placebo (Schneider-Helmert & Schoenenberger, 1986). - The increase in delta power was most pronounced in frontal derivations (Fz, F3, F4), consistent with the known frontal predominance of delta wave generation. - DSIP did not significantly change total sleep time or sleep onset latency — it RESTRUCTURED sleep toward more delta-rich slow-wave sleep at the expense of lighter NREM stages. - Multiple small crossover studies (n=6-16) in chronic insomniacs showed improved subjective sleep quality and increased slow-wave sleep duration without the "hangover" effect of benzodiazepines. **Neurochemical Mechanism:** - DSIP does not act through GABA receptors (unlike benzodiazepines, Z-drugs, and barbiturates). No GABA-A binding has been demonstrated. - It modulates multiple neurotransmitter systems: enhances serotonin synthesis in the dorsal raphe (5-HT is a delta wave promoter), reduces cortisol and ACTH secretion (stress axis dampening), and modulates glutamate/GABA balance in thalamocortical circuits. - The specific receptor for DSIP has never been definitively identified. This is a major gap in the literature. - DSIP is rapidly degraded by aminopeptidases in plasma (half-life ~7-15 minutes), yet its sleep effects last 6-8+ hours, suggesting it triggers a cascade rather than maintaining a receptor-bound state. ## Neuroendocrine System [Tier 2 — Human Data] DSIP suppresses cortisol and ACTH secretion, both acutely and over the sleep period. It modulates GH secretion (GH is naturally pulsatile during SWS — by increasing SWS, DSIP may indirectly enhance GH release). It reduces TSH levels slightly. The overall neuroendocrine profile is consistent with a "stress-dampening" peptide that facilitates the restorative endocrine environment of deep sleep. ## Pain Modulation [Tier 2 — Limited Human Data] DSIP has analgesic properties in animal models and limited human studies. Leu-enkephalin (an endogenous opioid) levels rise following DSIP administration. In small clinical studies on chronic pain patients, DSIP improved both pain scores and sleep quality — consistent with the known relationship between slow-wave sleep and pain modulation (deep sleep is anti-nociceptive). ## Addiction/Withdrawal [Tier 2 — Limited Human Data] Russian and European clinical studies from the 1980s-1990s reported that DSIP reduced withdrawal symptoms in alcohol and opioid dependence. The mechanism is attributed to normalization of sleep architecture (which is severely disrupted in substance withdrawal) and modulation of the HPA stress axis.

Practitioner Guide

## Sleep Architecture — Why Delta Waves Matter ### The Problem DSIP Addresses Modern sleep complaints are often not about QUANTITY but QUALITY. Many patients sleep 7-8 hours but wake unrefreshed because they are not spending enough time in deep slow-wave sleep (N3). This is particularly common in: - Adults over 40 (SWS declines dramatically with age — from 20% of sleep at age 20 to <5% at age 60) - Patients with chronic stress (cortisol suppresses delta waves) - Post-TBI patients (disrupted thalamocortical circuits) - Patients using benzodiazepines or Z-drugs (which paradoxically SUPPRESS delta waves while increasing total sleep time) ### How DSIP Differs From Conventional Sleep Aids | Feature | DSIP | Benzodiazepines/Z-drugs | Melatonin | |---------|------|------------------------|-----------| | Delta wave effect | Increases (+15-35%) | Decreases (-20-50%) | No significant effect | | Sleep architecture | Improves (more N3) | Worsens (less N3, less REM) | Minimal change | | Morning hangover | None | Common | None | | Dependence risk | None reported | High | None | | Sleep onset | Modest effect | Strong effect | Moderate effect | | Mechanism | Non-GABAergic | GABA-A potentiation | MT1/MT2 receptors | ### Dosing Protocols (From Published Clinical Studies) - **IV/IM route (research studies):** 25-30 nmol/kg (~60-75 mcg for a 70kg adult) given 30-60 minutes before desired sleep time. This is the most studied route. - **SC injection (off-label clinical use):** 100-300 mcg SC, 30-60 minutes before bed. SC dosing is higher due to slower absorption and incomplete bioavailability. - **Intranasal (experimental):** 100-200 mcg intranasal. Variable absorption. Some practitioners report this route is effective with less injection discomfort. - **Duration of use:** Typically cycled — 10-14 days on, 2-4 weeks off. Some Russian protocols use 5-day intensive courses. - **Timing:** Evening administration only (30-60 minutes before desired sleep time). Unlike sedatives, DSIP does not force sleep — it prepares the brain for deeper sleep when sleep occurs naturally. ### Building a Comprehensive Sleep Optimization Protocol DSIP can be one component of a multi-target sleep protocol: 1. **Sleep onset support:** Melatonin 0.3-1mg (physiological dose, not pharmacological) 30 min before bed — addresses circadian signaling. 2. **Delta wave enhancement:** DSIP 100-300 mcg SC — addresses sleep DEPTH. 3. **Cortisol management:** Ashwagandha 300mg standardized extract or phosphatidylserine 200mg at dinner — addresses the HPA axis contributor to shallow sleep. 4. **Magnesium:** 200-400mg magnesium glycinate or threonate at bedtime — supports GABA tone and muscle relaxation. 5. **Sleep hygiene:** Temperature (cool room), darkness, consistent timing — addresses circadian and environmental factors. ### What DSIP Cannot Do - It will NOT knock you out. It is not a sedative. Patients expecting an Ambien-like effect will be disappointed. - It will NOT help if the primary problem is circadian misalignment (jet lag, shift work). Melatonin and light therapy are more appropriate. - It will NOT overcome severe sleep-disordered breathing (OSA). CPAP/oral appliance is required first. - It works best for: non-refreshing sleep despite adequate duration, age-related loss of deep sleep, stress-disrupted sleep architecture, and post-benzodiazepine sleep recovery.

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No human safety data during pregnancy. Neuroactive peptide affecting sleep architecture and neuroendocrine function poses unknown risk to fetal development.
  Action: Do not use during pregnancy.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Neuroactive peptide exposure in nursing infant poses unknown risk.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Research peptide. Not for pediatric use.
  Action: Do not provide to individuals under 18.
• caution — General use
  DSIP has limited human safety data. While studied in small clinical trials for insomnia and alcohol withdrawal, comprehensive safety profiling has not been completed. Long-term effects unknown.
  Action: Use with awareness of limited evidence base. Monitor for unexpected neurological or endocrine effects.
• caution — CNS depressants (benzodiazepines, opioids, alcohol)
  DSIP promotes delta wave sleep and has sedative properties. Additive CNS depression when combined with benzodiazepines, opioids, alcohol, or other sedatives could impair consciousness and respiratory drive.
  Action: Avoid concurrent use with strong CNS depressants. If combined, reduce doses and monitor for excessive sedation.

Evidence

• The delta sleep-inducing peptide (DSIP): an update

  Schneider-Helmert D, Schoenenberger GA (1983) — Neuroscience and Biobehavioral Reviews — PMID: 6318875

  Review of delta sleep-inducing peptide (DSIP) covering its isolation, characterization, and effects on sleep architecture. DSIP modulates sleep-wake cycles, with clinical observations showing improvement in sleep quality in insomnia patients. Also noted effects on neuroendocrine regulation including ACTH, cortisol, and LH modulation. Limited by small sample sizes and methodological constraints of early studies.

  emerging

Stacks featuring this peptide

Research Summary

## Tier 1 — Strong Clinical Evidence - DSIP existence and isolation confirmed (Schoenenberger & Monnier, PNAS 1977) - Endogenous presence in human CSF and plasma confirmed by radioimmunoassay - General structure and sequence confirmed by multiple laboratories ## Tier 2 — Moderate Evidence - EEG studies showing 15-35% increase in delta wave power density during sleep after IV DSIP in controlled crossover designs (Schneider-Helmert & Schoenenberger, Eur Neurol 1986; multiple studies from 1980s-1990s) - Improved subjective sleep quality in chronic insomniacs without morning sedation (multiple small studies, n=6-30) - Cortisol and ACTH suppression confirmed in human pharmacodynamic studies - Analgesic effects in chronic pain patients (small studies) - Alcohol and opioid withdrawal symptom reduction (Russian clinical studies, moderate quality) ## Tier 3 — Preclinical/Theoretical - The DSIP receptor has never been identified — this is a major scientific gap. Without a known receptor, the molecular mechanism remains incompletely understood. - Rapid plasma degradation (half-life ~7-15 min) vs. prolonged biological effect (6-8 hours) suggests a "hit and run" mechanism (triggering a cascade) — intriguing but not fully elucidated - Potential neuroprotective effects (reduced oxidative stress markers in animal models of neurodegeneration) - Most clinical studies are from the 1980s-1990s with small sample sizes and are not up to modern clinical trial standards - No large-scale RCTs have ever been conducted - Synthetic analogs with improved stability (e.g., DSIP phosphorylated form) under preclinical investigation